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Abstract: Twelve tin(IV) compounds (  5  -  16  ) derived from four tridentate thiosemicarbazone
Schiff bases of 4-methyl-3-thiosemicarbazide with 2-hydroxy-3-methoxybenzaldehyde (
1, 2  ) and 4-phenyl-3-thiosemicarbazide with 2,3-dihydroxybenzaldehyde (  3, 4  ) of
general formulae of [R  2  Sn(L  n  )] and [Sn(L  n  )  2  ] (where R = Ph or Me; L  n  =  1
,  2  ,  3  and  4  ) were synthesized and characterized by elemental analysis, IR, UV-
vis, mass spectrometry and multinuclear NMR (  1  H,  13  C and  119  Sn)
spectroscopy. X-ray crystallographic data was obtained for  11′  , a 2:1 co-crystal
between Ph  2  Sn(L  2  ) (  11  ) and 3-methoxysalicylaldehyde azine, and Me  2  Sn(L
2  ) (  12  ); L  2  H  2  is 2-(2-hydroxy-3-methoxybenzylidene)-N-
phenylhydrazinecarbothioamide. The analysis revealed distinct coordination
geometries with  11  and 12 approaching trigonal-bipyramidal. In the crystal of  11′  ,
supramolecular dimers arising from amine-N–H  …  S(thiolate) hydrogen bonding and {
…  HNCS}  2  synthons are evident; π(chelate ring)  …  π(oxidobenzylidene) stacking
is also apparent. In the crystal of  12  , supramolecular, helical chains are generated by
a combination of amine-N–H  …  O(phenoxide) hydrogen bonding and Sn  …  S
secondary bonding. The cytotoxic activity of the compounds against a panel of ten
cancer cell lines, [HT29 (colon), U87 and SJ-G2 (glioblastoma), MCF-7 (breast), A2780
(ovarian), H460 (lung), A431 (skin), DU145 (prostate), BE2-C (neuroblastoma), and
MIA (pancreas) and one normal cell line, MCF-10A (normal breast)] were investigated.
The thiosemicarbazone Schiff bases  1  and  4  as well as the diphenyltin(IV)
compounds showed a strong ability to inhibit the growth of cancer cells, with particular
selectivity against HT29, MCF-7, A2780, A431, BE2-C, SJ-G2, and MIA cell lines. The
structure-activity relationship of all these compounds were studied by evaluating the
effect of alkyl and aryl groups attached at the thiosemicarbazone backbone, the
methoxy/hydroxyl groups present at the  meta  -position of the phenyl ring and alkyl or
aryl groups bound to the tin center.
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We have just now uploaded corrected files after review, in support of a paper 
entitled “Tin(IV) compounds of tridentate thiosemicarbazone Schiff bases: 
synthesis, characterization, in-silico analysis and in vitro cytotoxicity” by Enis 
Nadia Md Yusof, Alister J. Page, Jennette A. Sakoff, Michela I. Simone, Abhi 
Veerakumarasivam, Edward R. T. Tiekink  and Thahira B. S. A. Ravoof; that we 
wish to have considered for publication in Polyhedron.   
 
The structural and spectroscopic characterization, as well as the cytotoxicity of 
the compounds using a panel of cancer cell lines are described and discussed 
comprehensively. 
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 Thiosemicarbazone Schiff bases 1 and 4 are useful lead candidates for the future organic 
drug design development to treat cancers.  
 Diphenyltin(IV) compounds 5, 8, 11 and 14 exhibited excellent cytotoxic activity against all 
cancer cell lines tested.  
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Twelve tin(IV) compounds (5-16) derived from four tridentate thiosemicarbazone Schiff 
bases of 4-methyl-3-thiosemicarbazide with 2-hydroxy-3-methoxybenzaldehyde (1, 2) and 4-
phenyl-3-thiosemicarbazide with 2,3-dihydroxybenzaldehyde (3, 4) of general formulae of 
[R2Sn(L
n)] and [Sn(Ln)2] (where R = Ph or Me; L
n = 1, 2, 3 and 4) were synthesized and 
characterized by elemental analysis, IR, UV-vis, mass spectrometry and multinuclear NMR 
(1H, 13C and 119Sn) spectroscopy. X-ray crystallographic data was obtained for 11′, a 2:1 co-
crystal between Ph2Sn(L
2) (11) and 3-methoxysalicylaldehyde azine, and Me2Sn(L
2) (12); 


































































L2H2 is 2-(2-hydroxy-3-methoxybenzylidene)-N-phenylhydrazinecarbothioamide.  The 
analysis revealed distinct coordination geometries with 11 and 12 approaching trigonal-
bipyramidal.  In the crystal of 11′, supramolecular dimers arising from amine-N–
H…S(thiolate) hydrogen bonding and {…HNCS}2 synthons are evident; π(chelate 
ring)…π(oxidobenzylidene) stacking is also apparent.  In the crystal of 12, supramolecular, 
helical chains are generated by a combination of amine-N–H…O(phenoxide) hydrogen 
bonding and Sn…S secondary bonding. The cytotoxic activity of the compounds against a 
panel of ten cancer cell lines, [HT29 (colon), U87 and SJ-G2 (glioblastoma), MCF-7 (breast), 
A2780 (ovarian), H460 (lung), A431 (skin), DU145 (prostate), BE2-C (neuroblastoma), and 
MIA (pancreas) and one normal cell line, MCF-10A (normal breast)] were investigated. The 
thiosemicarbazone Schiff bases 1 and 4 as well as the diphenyltin(IV) compounds showed a 
strong ability to inhibit the growth of cancer cells, with particular selectivity against HT29, 
MCF-7, A2780, A431, BE2-C, SJ-G2, and MIA cell lines. The structure-activity relationship 
of all these compounds were studied by evaluating the effect of alkyl and aryl groups 
attached at the thiosemicarbazone backbone, the methoxy/hydroxyl groups present at the 
meta-position of the phenyl ring and alkyl or aryl groups bound to the tin center.  
 
1. Introduction 
Schiff bases that contain nitrogen, sulfur and oxygen as donor atoms such as 
thiosemicarbazones, semicarbazones, and dithiocarbazates and their metal complexes have 
been of interest since 1946 [1], owing to their remarkable biological and pharmacological 
properties, especially antitumor, antibacterial, antiviral, anti-tuberculosis, antifungal, and 
antimalarial activities [2], that are altered when small changes to the structures (e.g., 
changing of functional group) are applied. Thiosemicarbazones are considered as privileged 
ligands due to their potential donor atoms, π-delocalization and configurational flexibility that 
can produce various metal-ligand linkages [3]. Compounds having thiol groups have also 
been proven to inhibit the ribonucleotide reductase (RR) enzyme, used in DNA synthesis. 
Hence, by inhibiting or blocking the function of the RR enzyme, the DNA replication and 
synthesis of tumor cells can be controlled or prevented [4]. In many cases, complexation with 
metal ions increased the bioactivity of the compounds suggesting that coordination of such 



































































Although much research has been devoted to the synthesis, characterization and biological 
properties of ligands coordinated to transition metal ions. Tin-based compounds have 
received considerably less attention because of ecotoxicology effects at the biochemical, 
cellular, and organism level [5]. In recent years, tin-based compounds have been of great 
interest because of their ability to form stable bonds with hetero donor atoms, for instance 
nitrogen, sulfur and oxygen atoms [6–15]. Tin(IV) compounds are now well-known for their 
applications as cytotoxic, biocidal, antibacterial and antifungal agents [6,16–19]. Many 
studies have reported the antimicrobial activities of tin(IV) compounds derived from 
thiosemicarbazone Schiff bases. In particular, compounds containing the 3-
methoxysalicylaldehyde thiosemicarbazone Schiff base were tested for their in vitro 
cytotoxicity against human acute lymphoblastic leukemia (Jurkat cells) [20].  The data 
indicated increasing potency, in the order of dimethyltin(IV) < diphenyltin(IV) < 
dibutyltin(IV) compounds, with IC50 values of 260, 130, and 50 μM, respectively. This 
suggested that the cytotoxicity of dialkytin(IV) compounds increased with the increase in the 
length of the organic chain. The cytotoxicity of diphenyl- and dimethyltin(IV) compounds of 
pyruvic acid thiosemicarbazone have also been investigated against human breast 
adenocarcinoma (MCF-7), bladder carcinoma (T24), non-small cell lung carcinoma (A-549) 
and mouse fibroblast (L-929) cell lines with IC50 values in the range of 0.43 to 19.73 μΜ. The 
diphenyltin(IV) compound was most potent against T-24 cells with an IC50 value of 0.43 μΜ, 
where it exhibited 96-fold better activity than cisplatin [21]. 
 
Recently, tin(IV) compounds derived from tridentate 2-hydroxy-5-methoxybenzaldehyde-
N(4)-methylthiosemicarbazone exhibited higher anticancer activity against the human 
colorectal (HTC-116) cell line as compared to the reference drug, 5-fluorouracil [8]. The 
significant biological activity of the tin(IV) compounds were influenced by the types of 
organo group attached to the tin center, diffusion, lipophilicity, and steric effects [8,22–24].  
 
As a continuation of our research on tridentate ONS Schiff bases and their tin(IV) compounds 
[25,26], we report herein the preparation, spectroscopic characterization, and bioactivity of 
tin(IV) compounds (5-16) containing 2-hydroxy-3-methoxybenzyl- and 2,3-dihydroxybenzyl-
derived thiosemicarbazone Schiff bases (1-4). Diphenyl- (5, 8, 11, and 14) and 
dimethyltin(IV) (6, 9, 12, and 15) compounds exhibited penta-coordinated geometry whereas 
tin(IV) compounds were coordinated to two molecules of thiosemicarbazone Schiff bases (7, 


































































The experimental data (FTIR, electronic and single crystal X-ray diffraction analysis) of the 
synthesized compounds were in excellent agreement to the computed data as evidenced by 
density functional theory (DFT) calculations using B3LYP/LanL2DZ/6-311G(d,p) level of 
theory. The cytotoxicity of all compounds against a panel of ten cancer cell lines and one 
normal cell line was investigated. The results indicated that small differences in the structure 
of the compounds (Figure 1) had significant effects on their activity. These studies provide 
fundamental data for future drug design development in cancer treatment. 
 
Figure 1. The structure of thiosemicarbazone Schiff bases (1-4). 
 
2. Experimental 
2.1. Physical Measurements 
Melting points were determined using an Electrothermal digital melting point apparatus. IR 
spectra were recorded using the Perkin Elmer Spectrum 100 with Universal ATR Polarization 
in the range 4000–280 cm−1. C, H and N elemental analyses were carried out using a LECO 
CHNS-932 instrument. Molar conductivities of 10−3 M solutions of the organotin(IV) 
compounds in DMSO were measured at 27 °C using a Jenway 4310 conductivity meter fitted 
with a dip-type cell with a platinized electrode. Electronic spectra were recorded on a 
Shimadzu UV-1650 PC recording spectrophotometer (1000–200 nm). 1H- and 13C- NMR 
spectra were recorded using an NMR JNM ECA400 spectrometer. 119Sn NMR were 
measured using a Bruker BioSpin Avance III (600MHz) spectrometer. The mass spectra were 



































































All solvents and reagents were of analytical reagent grade and used without further 
purification. 
Chemicals: 4-methyl-3-thiosemicarbazide, 4-phenyl-3-thiosemicarbazide, potassium 
hydroxide, 2-hydroxy-3-methoxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 
dichlorodiphenyltin(IV), dichlorodimethyltin(IV), tin(II) chloride. Solvents: absolute ethanol, 
99.8%, ethanol, 95%, methanol and dimethylsulfoxide.  
2.3. Syntheses 
2.3.1. Syntheses of 2-(2-hydroxy-3-methoxybenzylidene)-N-methylhydrazinecarbothioamide 
(1) and 2-(2-hydroxy-3-methoxybenzylidene)-N-phenylhydrazinecarbothioamide (2) 
Compounds 1 and 2 were prepared according to the procedure described in the literature 
[27,28] with some modifications. 
4-Methylthiosemicarbazide (1.05 g, 10 mmol)/ 4-phenylthiosemicarbazide (1.67 g, 10 mmol) 
was dissolved in methanol (40 cm3) with stirring and heating (40°C) over a period of 30 
minutes. 3-Methoxysalicylaldehyde (1.52 g, 10 mmol) in 10 cm3 of methanol was added to 
the thiosemicarbazide solution and stirred at room temperature for 4 h. Upon cooling, a 
crystalline product began to form which was filtered, washed with cold methanol, and dried 
in a desiccator over anhydrous silica gel.  
2-(2-hydroxy-3-methoxybenzylidene)-N-methylhydrazinecarbothioamide (1) 
Colorless crystalline solid. Yield: 92 %. Melting point: 242-243°C. Analysis calculated for 
C10H13N3O2S: C, 50.19; H, 5.48; N, 17.56. Found: C, 49.93; H, 5.38; N, 17.22 %. FT-IR 
(ATR, cm-1): 3337 v(OH), 3304 v(NH), 1610 v(C=N), 1109 v(N-N), 1037 v(C=S). 1H- NMR 
(DMSO-d6) δ (ppm.): 2.99 (d, 3H, CH3), 3.79 (s, 3H, O-CH3), 6.93-7.54 (m, 3H, Ar-H), 8.37 
(s, 1H, CH), 8.39 (q, 1H, C(=S)-NH), 9.18 (s, 1H, OH), 11.42 (s, 1H, NH-N). 13C NMR 
(DMSO-d6) δ (ppm.): 30.8 (N-CH3), 56.4 (O-CH3), 113.1, 118.2, 119.2, 121.2, 139.6, 146.7 
(Ar-C), 148.4 (C=N), 177.6 (C=S). 
2-(2-hydroxy-3-methoxybenzylidene)-N-phenylhydrazinecarbothioamide (2)  
White crystalline solid. Yield: 90 %. Melting point: 209-210°C. Analysis calculated for 
C15H15N3O2S: C, 59.78; H, 5.02; N, 13.94. Found: C, 59.99; H, 5.15; N, 13.80 %. FT-IR 
(ATR, cm-1): 3300 v(NH), 1609 v(C=N), 1103 v(N-N), 908 v(C=S). 1H NMR (DMSO-d6) δ 


































































11.78 (s, 1H, NH-N). 13C NMR (DMSO-d6) δ (ppm.): 56.3 (O-CH3), 113.4, 118.8, 119.5, 
121.2, 125.4, 126.4, 128.6, 139.7, 140.4, 146.6 (10 x aromatic-C), 148.6 (C=N), 176.1 (C=S). 
2.3.2. Syntheses of 2-(2,3-dihydroxybenzylidene)-N-methylhydrazinecarbothioamide (3) and 
2-(2,3-dihydroxybenzylidene)-N-phenylhydrazinecarbothioamide (4) 
Compounds 3 and 4 were prepared according to the procedure described in the literature 
[29,30]. A 25 cm3 ethanolic solution of 2,3-dihydroxybenzaldehyde (1.38 g, 10 mmol) was 
added to an equimolar ethanolic solution (10 cm3) of 4-methyl-3-thiosemicarbazide (1.05 g, 
10 mmol)/4-phenyl-3-thiosemicarbazide (1.67 g, 10 mmol). The mixture was stirred for 3 
hours at room temperature and the title compound was filtered. The title compound was then 
recrystallized from methanol to remove all the impurities and kept in desiccator over 
anhydrous silica gel. 
2-(2,3-dihydroxybenzylidene)-N-methylhydrazinecarbothioamide (3) 
Pale yellow solid. Yield: 83 %. Melting point: 231-232°C. Analysis calculated for 
C9H11N3O2S: C, 47.99; H, 4.92; N, 18.65. Found: C, 46.88; H, 4.85; N, 18.38 %. FT-IR 
(ATR, cm-1): 3418 v(OH), 3140 v(NH), 1601 v(C=N), 1112 v(N-N), 1035 v(C=S). 1H NMR 
(DMSO-d6) δ (ppm.): 3.00 (d, 3H, CH3), 6.67-7.38 (m, 3H, Ar-H), 9.02 (s, 1H, CH), 8.37, 
8.38 (2 x s, 2H, OH), 9.49 (s, 1H, C(=S)-NH), 11.40 (s, 1H, NH-N). 13C NMR (DMSO-d6) δ 
(ppm.): 31.3 (N-CH3), 116.7, 117.4, 119.4, 121.5, 140.1, 145.6 (Ar-C), 146.0 (C=N), 178.0 
(C=S). 
2-(2,3-dihydroxybenzylidene)-N-phenylhydrazinecarbothioamide (4) 
Pale yellow solid. Yield: 70 %. Melting point: 215-216°C. Analysis calculated for 
C14H13N3O2S: C, 58.52; H, 4.56; N, 14.62. Found: C, 57.61; H, 4.69; N, 14.67 %. FT-IR 
(ATR, cm-1): 3443 v(OH), 3129 v(NH), 1597 v(C=N), 1047 v(N-N), 1029 v(C=S). 1H NMR 
(DMSO-d6) δ (ppm.): 6.67-7.57 (m, 8H, Ar-H), 8.49 (s, 1H, CH), 8.96, 9.52 (2 x s, 2H, OH), 
10.01 (s, 1H, C(=S)-NH), 11.75 (s, 1H, NH-N). 13C NMR (DMSO-d6) δ (ppm.): 117.1, 117.9, 



































































2.3.3. General procedure for the synthesis of tin(IV) compounds derived from 1 and 3 
To a solution of 1 (0.24 g, 1 mmol)/ 3 (0.23 g, 1 mmol) in 100 cm3 of methanol, KOH (0.11 
g, 2 mmol) was added and the mixture was stirred and heated for 30 minutes in methanol. 
Then, 1 mmol of tin precursor (Ph2SnCl2 (0.34 g)/ Me2SnCl2 (0.22 g)/ SnCl2 (0.19 g)) was 
added to the mixture and refluxed for 2 hours under nitrogen. The mixture was filtered while 
hot and then the filtrate was placed in the freezer until a bright yellow solid formed. The solid 
residue obtained was recrystallized from methanol. 
Diphenyltin(IV) compound of 2-(2-hydroxy-3-methoxybenzylidene)-N-methylhydrazine 
carbothioamide (5) 
Bright yellow solid. Yield: 74 %. Melting point: 138-139°C. Analysis calculated for 
C22H21N3O2SSn: C, 51.79; H, 4.15; N, 8.24. Found: C, 51.03; H, 4.23; N, 8.16 %. FT-IR 
(ATR, cm-1): 3299 v(N-H), 1596 v(C=N), 1066 v(N-N), 973 v(C=S). 1H NMR (CDCl3) δ 
(ppm.): 3.01 (d, 3H, N-CH3), 3.96 (s, 3H, O-CH3), 7.96 (s, 1H, CH), 7.36-8.12 (m, 13H, Ar-
H), 8.59 (s, 1H, NH). 13C NMR (CDCl3) δ (ppm.): 29.8 (NH-CH3), 56.5 (O-CH3), 115.7, 
116.7, 117.2, 125.1, 128.6, 129.9, 135.9, 142.5, 151.6 (Ar-C), 157.1 (C=N), 160.3 (S-C-S). 
119Sn NMR (CDCl3) δ (ppm.): -236. 
Dimethyltin(IV) compound of 2-(2-hydroxy-3-methoxybenzylidene)-N-methylhydrazine 
carbothioamide (6) 
Bright yellow solid. Yield: 42 %. Melting point: 164-168°C. Analysis calculated for 
C12H17N3O2SSn: C, 37.33; H, 4.44; N, 10.88. Found: C, 39.00; H, 4.76; N, 11.00 %. FT-IR 
(ATR, cm-1): 3222 v(N-H), 1590 v(C=N), 1066 v(N-N), 973 v(C=S). 1H NMR (CDCl3) δ 
(ppm.): 0.91 (s, 6H, Sn-CH3), 2.97 (d, 3H, N-CH3), 3.94 (s, 3H, O-CH3), 7.26 (s, 1H, CH), 
6.66-6.87 (m, 3H, Ar-H), 8.55 (s, 1H, NH). 13C NMR (CDCl3) δ (ppm.): 8.7 (Sn-CH3), 31.3 
(NH-CH3), 56.4 (O-CH3), 115.7, 115.8, 117.8, 118.5, 125.8, 151.3 (Ar-C), 156.5 (C=N), 
178.0 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): -154. 
Tin(IV) compound of 2-(2-hydroxy-3-methoxybenzylidene)-N-methylhydrazine 
carbothioamide (7) 
Compound 7 was prepared following the same procedure as described for 5, using 1 (0.48 g, 
2 mmol). Bright yellow solid. Yield: 31 %. Melting point: 118-119°C. Analysis calculated for 


































































(ATR, cm-1): 3308 v(N-H), 1590 v(C=N), 1066 v(N-N), 973 v(C=S). 1H NMR (DMSO-d6) δ 
(ppm.): 2.36 (d, 6H, N-CH3), 3.82 (s, 6H, O-CH3), 7.60 (s, 2H, CH), 6.67-7.31 (m, 6H, Ar-
H), 8.88 (s, 2H, NH). 13C NMR (DMSO-d6) δ (ppm.): 19.3 (NH-CH3), 56.7 (O-CH3), 105.4, 
116.7, 117.4, 126.5, 128.6, 129.0, 130.7, 130.8, 134.9, 149.7, 151.8, 158.3 (Ar-C), 163.7 
(C=N), 170.6 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): -354. 
Diphenyltin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-methylhydrazine 
carbothioamide (8)  
Yellow solid. Yield: 49 %. Melting point: 186-192°C. Analysis calculated for 
C21H19N3O2SSn: C, 50.83; H, 3.86; N, 8.47. Found: C, 48.06; H, 4.27; N, 8.02 %. FT-IR 
(ATR, cm-1): 1593 v(C=N), 1006 v(N-N), 953 v(C=S). 1H NMR (DMSO-d6) δ (ppm.): 3.00 
(s, 3H, NH-CH3), 8.57 (s, 1H, CH), 6.37-8.20 (m, 13H, Ar-H), 11.27 (s, 1H, NH). 
13C NMR 
(DMSO-d6) δ (ppm.): 30.9 (NH-CH3), 112.8, 113.7, 115.7, 118.4, 128.3, 129.2, 136.0, 136.1, 
141.1, 145.4, 153.3 (aromatic-C), 154.3 (C=N), 177.0 (S-C-S). 119Sn NMR (DMSO-d6) δ 
(ppm.): -227. 
Dimethyltin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-methylhydrazine 
carbothioamide (9)  
Yellow solid. Yield: 32 %. Melting point: 223-225°C. Analysis calculated for 
C11H15N3O2SSn: C, 35.51; H, 4.06; N, 11.29. Found: C, 35.87; H, 3.86; N, 11.35 %. FT-IR 
(ATR, cm-1): 1596 v(C=N), 1006 v(N-N), 951 v(C=S). 1H NMR (DMSO-d6) δ (ppm.): 0.62 
(s, 6H, Sn-CH3), 3.00 (d, 3H, N-CH3), 6.32-7.10 (m, 3H, Ar-H), 8.38 (s, 1H, CH), 11.30 (s, 
1H, NH). 13C NMR (DMSO-d6) δ (ppm.): 6.8 (Sn-CH3), 30.7 (NH-CH3), 112.6, 113.7, 115.6, 
118.6, 140.7, 153.9 (Ar-C), 155.0 (C=N), 177.2 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): -
123. 
Tin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-methylhydrazinecarbothioamide (10)  
Compound 10 was prepared following the same procedure as described for 5, using 1 (0.46 g, 
2 mmol). Orange solid. Yield: 79 %. Melting point: >300°C. Analysis calculated for 
C18H18N6O4S2Sn: C, 38.25; H, 3.21; N, 14.87. Found: C, 36.62; H, 2.92; N, 14.21 %. FT-IR 
(ATR, cm-1): 1585 v(C=N), 993 v(N-N), 951 v(C=S). 1H NMR (DMSO-d6) δ (ppm.): 2.83 (s, 


































































13C NMR (DMSO-d6) δ (ppm.): 30.6 (NH-CH3), 113.8, 114.3, 116.7, 118.9, 140.0. 150.1 
(Ar-C), 150.6 (C=N), 177.5 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): 519. 
2.3.4. General procedure for the syntheses of tin(IV) compounds derived from 2 
Compound 2 (0.30 g, 1 mmol) was dissolved in methanol (100 cm3) and Et3N (0.28 cm
3, 2 
mmol) was added dropwise to the solution of 2. The mixture was heated (40°C) for about 2 
hours until the solution was reduced by half. Next 1 mmol of tin precursor (Ph2SnCl2 (0.34 
g)/Me2SnCl2 (0.22 g)/ SnCl2 (0.19 g)) was added to the mixture.  The mixture was refluxed 
under nitrogen for about 2 hours and filtered while hot to remove triethylamine salt and the 
filtrate was kept at room temperature until a bright yellow product formed. 
Diphenyltin(IV) compound of 2-(2-hydroxy-3-methoxybenzylidene)-N-phenylhydrazine 
carbothioamide (11) 
Yellow crystals. Yield: 73 %. Melting point: 205-207°C. Analysis calculated for 
C27H23N3O2SSn: C, 56.67; H, 4.05; N, 7.34%. Found: C, 57.53; H, 4.26; N, 7.87%. FT-IR 
(ATR, cm-1): 3331 v(N-H), 1586 v(C=N), 1075 v(N-N), 832 v(C=S). 1H NMR (CDCl3) δ 
(ppm.): 3.96 (s, 3H, O-CH3), 7.99 (s, 1H, CH), 6.69-7.56 (m, 18H, Ar-H), 8.70 (s, 1H, NH). 
13C NMR (CDCl3) δ (ppm.): 56.7 (O-CH3), 115.2, 116.2, 116.9, 119.4, 120.7, 123.4, 124.1, 
125.4, 128.7, 128.9, 130.0, 135.9, 139.3, 142.1, 148.3, 149.7, 151.7 (Ar-C), 162.5 (C=N), 
164.8 (S-C-S). 119Sn NMR (CDCl3) δ (ppm.): -242. 
Dimethyltin(IV) compound of 2-(2-hydroxy-3-methoxybenzylidene)-N-phenylhydrazine 
carbothioamide (12)  
Yellow crystals. Yield: 64 %. Melting point: 176-179°C. Analysis calculated for 
C17H19N3O2SSn: C, 45.56; H, 4.27; N, 9.38%. Found: C, 45.86; H, 4.40; N, 7.08%. FT-IR 
(ATR, cm-1): 3294 v(N-H), 1577 v(C=N), 1059 v(N-N), 824 v(C=S). 1H NMR (CDCl3) δ 
(ppm.): 3.85 (s, 3H, O-CH3), 7.53 (s, 1H, CH), 6.69-7.32 (m, 8H, Ar-H), 8.65 (s, 1H, NH). 
13C NMR (CDCl3) δ (ppm.): 6.5 (Sn-CH3), 56.2 (O-CH3), 115.3, 116.6, 116.7, 120.5, 123.3, 
125.4, 128.9, 139.4, 151.3, 156.8 (Ar-C), 162.5 (C=N), 163.9 (S-C-S). 119Sn NMR (CDCl3) δ 
(ppm.): -115. 



































































Compound 13 was prepared following the same procedure as described for 11, using 2 (0.60 
g, 2 mmol). Yellow solid. Yield: 50 %. Melting point: 293-294°C. Analysis calculated for 
C30H26N6O4S2Sn: C, 50.23; H, 3.65; N, 11.71%. Found: C, 49.85; H, 3.73; N, 11.60%. FT-IR 
(ATR, cm-1): 3303 v(N-H), 1581 v(C=N), 1063 v(N-N), 824 v(C=S). 1H NMR (DMSO-d6) δ 
(ppm.): 3.58 (s, 6H, O-CH3), 9.08 (s, 2H, CH), 6.80-7.73 (m, 16H, Ar-H), 9.70 (s, 2H, NH). 
13C NMR (DMSO-d6) δ (ppm.): 56.4 (O-CH3), 117.9, 118.2, 121.0, 123.4, 126.8, 129.2, 
140.4, 151.4, 154.8 (Ar-C), 160.3 (C=N), 162.2 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): -
451. 
2.3.5. General procedure for the synthesis of tin(IV) compounds derived from 4 
Compound 4 (0.29 g, 0.001 mol) was dissolved in methanol (100 cm3) and KOH (0.11 g, 2 
mmol) was added dropwise to the solution of 4. The mixture was refluxed for about 30 
minutes, where the color changed from light yellow to orange. Next 1 mmol of tin precursor 
(Ph2SnCl2 (0.34 g)/Me2SnCl2 (0.22 g)/SnCl2 (0.19 g)) was added to the mixture.  The mixture 
was refluxed for 6 hours and filtered while hot to remove triethylamine salt and the filtrate 
was kept at room temperature until the product, an orange precipitate, formed. 
Diphenyltin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-phenylhydrazine 
carbothioamide (14)  
Orange solid. Yield: 71 %. Melting point: 133-137 °C. Analysis calculated for 
C26H21N3O2SSn: C, 55.94; H, 3.79; N, 7.53%. Found: C, 56.30; H, 3.99; N, 7.42%. FT-IR 
(ATR, cm-1): 1587 v(C=N), 998 v(N-N), 957 v(S-C-S). 1H NMR (DMSO-d6) δ (ppm.): 6.57-
9.52 (m, 18H, Ar-H), 9.87 (s, 1H, CH), 11.69 (s, 1H, NH). 13C NMR (DMSO-d6) δ (ppm.): 
120.5, 120.7, 125.4, 125.5, 125.6, 125.7, 128.5, 128.6, 128.7, 128.8, 128.9, 129.0, 129.1, 
129.5, 134.6, 135.2, 135.5, 136.3, 136.4, 136.7, 139.7 (Ar-C), 148.8 (C=N), 175.2 (S-C-S).  
119Sn NMR (DMSO-d6) δ (ppm.): -328. 
Dimethyltin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-phenylhydrazine 
carbothioamide (15) 
Orange solid. Yield: 42 %. Melting point: 153-156°C. Analysis calculated for 
C16H17N3O2SSn: C, 44.27; H, 3.95; N, 9.68. Found: C, 44.32; H, 3.72; N, 9.90%. FT-IR 
(ATR, cm-1): 1575 v(C=N), 1001 v(N-N), 917 v(S-C-S). 1H NMR (DMSO-d6) δ (ppm.): 0.63 



































































(DMSO-d6) δ (ppm.): 7.1 (Sn-CH3), 110.2, 114.7, 128.3, 128.4, 128.7, 128.8, 135.3, 152.1, 
152.7, 153.6 (Ar-C), 153.8 (C=N), 167.5 (S-C-S). 119Sn NMR (DMSO-d6) δ (ppm.): -103. 
Tin(IV) compound of 2-(2,3-dihydroxybenzylidene)-N-phenylhydrazinecarbothioamide (16) 
Compound 16 was prepared following the same procedure as described for 14, using 4 (0.58 
g, 2 mmol). Orange solid. Yield: 48 %. Melting point: >300 °C. Analysis calculated for 
C28H22N6O4S2Sn: C, 48.78; H, 3.22; N, 12.19%. Found: C, 48.30; H, 2.97; N, 12.52 %. FT-
IR (ATR, cm-1): 1588 v(C=N), 1001 v(N-N), 939 v(S-C-S). 1H NMR (DMSO-d6) δ (ppm.): 
6.66-7.55 (m, 16H, Ar-H), 8.48 (s, 2H), 10.00 (s, 2H, CH), 11.74 (s, 2H, NH). 13C NMR 
(DMSO-d6) δ (ppm.): 117.1, 119.5, 121.2, 125.6, 125.7, 125.9, 126.0, 128.4, 128.5, 128.5, 
139.6 (Ar-C), 145.9, 146.0 (C=N), 175.7, 176.1 (S-C-S).  119Sn NMR (DMSO-d6) δ (ppm.): -
541. 
 
2.4. X-ray Structure Determination 
Intensity data for light-yellow crystals of 11′ (0.05 × 0.08 × 0.12 mm) and 12 (0.07 × 0.13 × 
0.18 mm) a were measured at 150 K on an Oxford Diffraction Gemini Eos CCD 
diffractometer (Rigaku Oxford Diffraction, United Kingdom) fitted with Mo Kα radiation (λ 
= 0.71073 Å).  Data reduction and empirical absorption corrections, based on a multi-scan 
technique, were applied [31].  The structures were solved by direct methods [32], and refined 
on F2 with anisotropic displacement parameters and C-bound H atoms in the riding model 
approximation [33].  The oxygen- and nitrogen-bound H atoms were refined with distance 
restraints of O‒H = 0.84 ± 0.01 Å and N‒H = 0.88 ± 0.01 Å, respectively.  A weighting 
scheme of the form w = 1/[σ2(Fo
2) + (aP)2], where P = (Fo
2 + 2Fc
2)/3, was introduced in each 
case; for 11′ a = 0.033 and for 12 a = 0.022.  The absolute structure of 12 was determined 
based on differences in Friedel pairs included in the data set.  The molecular structure 
diagrams were generated at the 70% probability level by ORTEP for Windows [34], and the 
packing diagrams were prepared with DIAMOND [35].  Additional analysis was conducted 
with PLATON [36]. 
Crystal data for 11′: C27H23N3O2SSn, 0.5(C16H16N2O4), M = 722.43, monoclinic, P21/c, a = 
14.7977(5), b = 13.0726(4), c = 17.0997(6) Å, β = 105.421(3)°, V = 3188.75(19) Å3, Z = 4, 
Dx = 1.505 g cm


































































(θmax = 29.4°), no. independent reflections = 7337, no. reflections with I ≥ 2σ(I) = 5378, R 
(obs. data) = 0.041, and wR2 (all data) = 0.087.  CCDC deposition number: 1975499. 
Crystal data for 12: C17H19N3O2SSn, M = 448.10, orthorhombic, P212121, a = 7.7253(2), b = 
12.4692(3), c = 18.2692(5) Å, V = 1759.84(8) Å3, Z = 4, Dx = 1.691 g cm
−3, F(000) = 896, 
and μ = 1.585 mm−1.  No. reflections measured = 11201 (θmax = 29.3°), no. independent 
reflections = 4191, no. reflections I ≥ 2σ(I) = 3900, R (obs. data) = 0.030, and wR2 (all data) = 
0.096.  CCDC deposition number: 1975500. 
 
2.5. Density Functional Theory (DFT) calculations 
DFT calculations were performed using Gaussian09 (Gaussian Inc., Wallingford, CT, USA) 
[37] and Gaussview5 (Semichem, Inc., Shawnee Mission, KS, USA) [38] software. The 
molecular structures and geometries of the Schiff bases and tin(IV) compounds were fully 
optimized using DFT method with the B3LYP [39,40] hybrid exchange correlation functional 
with LanL2DZ pseudopotential on Sn [41–43] and 6-311G(d,p) Pople basis set for all other 
atoms. The initial single crystal X-ray molecular structures and geometries for the tin 
compounds in 11 and 12 were used for DFT calculations using the same functional and basis 
set. Vibrational frequencies were scaled using a scaling factor of 0.9682 [44]. The electronic 
stabilities of the optimized geometries were computed using the time-dependent density 
functional theory (TD-DFT) formalism [45,46] and included solvation effects (DMSO) via 
the polarizable continuum method (PCM) [47–49], using the same basis set. These DFT were 
performed in the same way as reported in a previous publication [25]. 
 
2.6. In Vitro Cytotoxic Assay 
The cytotoxicity of tin(IV) compounds against HT29 (colon), U87 and SJ-G2 (glioblastoma), 
MCF-7 (breast), A2780 (ovarian), H460 (lung), A431 (skin), DU145 (prostate), BE2-C 
(neuroblastoma), and MIA (pancreas) cell lines and one normal breast cell line, MCF-10A 
were performed by the MTT assay using the same method as previously reported [25,50,51]. 
 
Cell Culture and Stock Solutions. Stock solutions were prepared as follows and stored at −20 
°C: Trial compounds were stored as 10 mM solutions in DMSO. All cell lines were cultured 


































































Dulbecco’s modified Eagle’s medium (DMEM) (Trace Biosciences) supplemented with 10% 
fetal bovine serum, 10 mM sodium bicarbonate, penicillin (100 IU/mL), streptomycin (100 
μg/mL) and glutamine (4 mM). The normal cell line, MCF-10A, was cultured in DMEM:F12 
(1:1) cell culture media, 5% heat inactivated horse serum, supplemented with penicillin (50 
IU/mL), streptomycin (50 μg/mL), 20mM Hepes, L-glutamine (2 mM), epidermal growth 
factor (20 ng/mL), hydrocortisone (500 ng/mL), cholera toxin (100 ng/mL), and insulin (10 
μg/mL). 
 
In Vitro Growth Inhibition Assay. Cells in logarithmic growth were transferred to 96-well 
plates. Cytotoxicity was determined by plating cells in duplicate in 100 μL medium at a 
density of 2500–4000 cells/well. On day 0 (24 h after plating), when the cells were in 
logarithmic growth, 100 μL medium, with or without the test agent, was added to each well. 
After 72 h drug exposure, growth inhibitory effects were evaluated using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay and absorbance read at 540 
nm. Percentage growth inhibition was determined at a fixed drug concentration of 25 μM. A 
value of 100% was indicative of complete cell growth inhibition. Those analogs showing 
appreciable percentage growth inhibition underwent further dose response analysis allowing 
for the calculation of a GI50 value. This value is the drug concentration at which cell growth 
is 50% inhibited based on the difference between the optical density values on day 0 and 
those at the end of drug exposure [52,53]. 
 
 
3. Results and discussion 
3.1. Synthesis 
The synthetic pathway of the Schiff bases (1-4) and their tin(IV) compounds (5-16) are 
indicated in Schemes 1 and 2. The Schiff bases were synthesized by the condensation 
reaction between 2-hydroxy-3-methoxybenzaldehyde/ 2,3-dihydroxybenzaldehyde and the 
corresponding thiosemicarbazide (4-methyl-3-thiosemicarbazide and 4-phenyl-3-
thiosemicarbazide) in alcoholic solution, which was as previously reported [27,54,55]. The 
Schiff bases were then reacted with Ph2SnCl2, Me2SnCl2 and SnCl2 separately, in the 
presence of potassium hydroxide (KOH)/ triethyamine (Et3N) by conventional methods or 
under reflux. The isolated yellow or orange colored tin(IV) compounds were achieved in 


































































instability at room temperature. The tin(IV) compounds were soluble in most organic 
solvents especially dimethylsulfoxide (DMSO) and dimethylformamide (DMF). The molar 
conductance values of the compounds were in the range 0.88-7.85 Ω-1 cm2 mol-1, which was 
well below than 25 Ω-1 cm2 mol-1 indicating that all of them were non-electrolytic in nature. 
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R1 = CH3,   R2 = OCH3  (5)
R1 = CH3,   R2 = OH      (8)
R1 = C6H5,  R2 = OCH3 (11)
R1 = C6H5,  R2 = OH      (14)
R1 = CH3,   R2 = OCH3  (6)
R1 = CH3,   R2 = OH      (9)
R1 = C6H5,  R2 = OCH3 (12)
R1 = C6H5,  R2 = OH      (15)
R1 = CH3,   R2 = OCH3  (7)
R1 = CH3,   R2 = OH      (10)
R1 = C6H5,  R2 = OCH3 (13)
R1 = C6H5,  R2 = OH      (16)
Scheme 2. Synthetic pathway of thiosemicarbazone Schiff bases to tin(IV) compounds 
(5-16)  
 
3.2. Spectroscopic and spectrometric data 
 



































































The experimental and calculated frequencies in the infrared spectra of thiosemicarbazone 
Schiff bases (1-4) and their tin(IV) compounds (5-16) were determined in the range of 4000-
280 cm-1 and 4000-0 cm-1, respectively. Important infrared vibrations and their assignments 
are summarized in Table S1 for both experimental and calculated frequencies. The calculated 
frequencies were employed to assign prominent peaks with maximum accuracy, which 
resulted in excellent correlation with experimental data (Figure S1). In the spectra of 1 and 2, 
the v(OH) was not observed, which suggested that the v(OH) band overlapped with the v(N-
H) band due to hydrogen bonding (NH...OH) between the two groups [57,58]. The v(OH) 
was observed in the calculated spectra because they were generated from the gas phase 
structures, while experimental spectra were analyzed in the solid state where the compounds 
are in a more concentrated form, resulting in either intermolecular and/or intramolecular 
hydrogen bonding similar to that observed in structurally-related Schiff bases [23,59,60]. 
Conversely, v(OH) was observed in the spectra of 3 and 4 which were comparable to 
previous literature [23]. As a result, the loss of v(OH) upon complexation was difficult to 
assign by FTIR alone, due to the intra- and intermolecular hydrogen bonding between the 
molecules. The v(N-H) of thiosemicarbazone Schiff bases disappeared upon complexation 
due to the deprotonation of NH and the involvement of resulting nitrogen atom in 
coordination to the Sn center. Furthermore, the IR spectra of 1, 2, 3 and 4 exhibited a strong 
intensity band due to the presence of v(C=N)azomethine at 1610, 1609, 1601 and 1597 cm
-1, 
respectively. This band shifted to lower frequencies in the spectra of tin(IV) compounds 
suggesting coordination to the tin center via the azomethine nitrogen atom. Other than that, 
the v(C=S) and v(N-N) absorptions shifted to lower frequencies upon complexation, 
indicating coordination via thiolate sulfur and azomethine nitrogen forming five-membered 
chelate rings. A small deviation was observed in the vibrational frequencies which can be 
explained by the fact that the experimental spectra was obtained in the solid state, while DFT 
calculations were run in the gas phase. 
 
3.2.2. Multinuclear (1H-, 13C- and 119Sn-) NMR spectral analysis 
The 1H- and 13C- NMR spectra of 1-4 were recorded in DMSO-d6 solution and 5-16 were 
recorded in DMSO-d6/CDCl3 solution at room temperature. The assignments of the relevant 
signals are compiled in Tables S2 and S3. The 1H-NMR spectra of 1-4 showed signals at 
11.42, 11.78, 11.40 and 11.75 ppm, respectively, which indicated the presence of -NH- 
protons. These -NH- proton signals were not present in the spectra of the tin(IV) compounds 


































































Proton signals appeared at 9.18 and 10.02 ppm for 1 and 2 corresponding to the hydroxyl 
atom, which disappeared in the 1H- NMR spectra of tin(IV) compounds indicating the 
coordination of the hydroxyl proton to the tin center [61]. Contrastingly, the two signals for 
hydroxyl groups at 8.37, 8.38 ppm (3) and 8.96, 9.52 ppm (4) disappeared upon 
complexation, which indicated the presence of intra- and intermolecular hydrogen bonding in 
the compounds [23,62]. 
 
The 13C- NMR spectra of 1, 2, 3, and 4 showed carbon signals at 177.6, 176.1, 178.0, and 
176.0 ppm, respectively at the downfield region attributed to -S-C(=S)N. The position of 
these carbon signals proved that the compounds are predominately thione tautomers even in 
DMSO-d6 solution. The signals shifted to the upfield region in the spectra of tin(IV) 
compounds indicative of the involvement of -S-C(-S)N in the complexation, and decreasing 
electron density at the carbon atom when sulfur was chelated to the tin atom. The C=N signal 
was assigned at 148.4, 148.6, 146.0, and 146.0 ppm for 1-4, respectively, and appeared 
downfield as the carbon atom was bonded to the electronegative atoms. However, the C=N 
signals shifted downfield in the spectra of tin(IV) compounds due to the increasing electron 
density around the atom upon complexation. The -CH3- of the methoxy group appeared at the 
upfield region at 56.4 (1) and 56.3 ppm (2). A similar carbon signal was observed for the -
CH3- of the methoxy group in the spectra of tin(IV) compounds indicating that the methoxy 
group did not coordinate to the tin atom. 
  
119Sn- NMR was used to predict the geometry of the tin-containing compounds. The 119Sn-
NMR spectra of compounds 5-16 were evaluated in DMSO/CDCl3 solutions, at room 
temperature using SnCl4 (δ = -150 ppm) as an external standard. The 
119Sn chemical shift 
strongly depends on the alkyl/aryl group attached to the tin atom and the electronegativity of 
the ligand coordinated to the tin atom as well as temperature employed in the experiments. 
Theoretically, as the coordination number increases, the 119Sn chemical shift moves towards 
the shielding region [63]. The spectra showed one sharp signal which indicated that the 
tin(IV) compounds had only a single tin atom species. The 119Sn NMR values of penta-
coordinated diphenyl- (5, 8, 11, and 14) and dimethyltin(IV) (6, 9, 12, and 15) compounds 
fell in the range of -227 to -328 and -103 to -154 ppm, respectively, similar to that reported 
previously for diphenyl- and dimethyltin(IV) compounds [64–67]. The 119Sn NMR values of 
hexa-coordinated tin(IV) compounds (7, 10, 13, and 16) were observed in the range of -354 


































































to the presence of hydroxyl groups at the meta position, which were more electronegative 
than the methoxy groups [68].  
 
3.2.3. Mass spectrometric analysis 
Mass spectral data for 1-4 were recorded in DMSO and were found to be consistent with the 
proposed formulation of the Schiff bases. The mass spectra displayed prominent peaks at m/z 





+ ions; the mass spectra 
for 1-4 are supplied in Figure S2. 
 
3.2.4 Electronic spectral analysis 
The experimental and calculated electronic data of compounds 1-16 in DMSO are tabulated 
in Table S4. The prominent experimental electronic absorptions for 1-4 were observed in the 
range of 328-334 nm, which were best correlated with the calculated absorptions by B3LYP 
in the range of 317-330 nm. The frontier molecular orbitals of compounds 1-16 are shown in 
Figure S3, where the figure illustrated the excitation of electrons from HOMO of non-
bonding electrons at sulfur and nitrogen atoms that were excited to the LUMO which was 
largely centered on the thiosemicarbazone backbone, 2,3-dihydroxy phenyl ring and as well 
as the oxygen atom attached to the phenyl ring. Thus, this supported the transition of 
electrons from n→π* and π→π* of the Schiff bases. For tin(IV) compounds (5-16), the 
HOMOs were largely centered on the thiosemicarbazone Schiff base, whereas the LUMOs 
were centered on the entire thiosemicarbazone Schiff base except the methyl or phenyl 
groups attached to the nitrogen atom, thiolate sulfur and oxygen atoms attached to the phenyl 
ring.   
 
3.3. X-ray structure crystallography of 11’ and 12 
3.3.1. Molecular structures 
The crystallographic asymmetric unit of 11′ comprises a molecule of Ph2Sn(L
2) (11) and half 
a molecule of 3-methoxysalicylaldehyde azine with the molecular structures of each shown in 
Figure 2.  The presence of the azine molecule in 11′ presumably arises from the prolonged 
standing of the acetonitrile:methanol (1:1) solution during crystallization of an authenticated 
sample of 11 which resulted in partial decomposition of 11 and subsequent condensation of 


































































carbon atoms of the phenyl substituents as well as the imine-N, phenoxide-O and thiolate-S 
atoms derived from the di-negative, tridentate Schiff base ligand.  The resulting coordination 
geometry defined by the C2NOS donor set is highly distorted, being ideal trigonal-
bipyramidal geometry.  This is quantified by the value of τ = 0.60 which lies between the 
extreme values of 1.0 and 0.0 for the aforementioned ideal geometries [69].  The angle 
closest to being trans is the S1–Sn–O1 angle of 161.81(7)° with the next widest angle of 
125.85(10)° being for N2–Sn–C16.  Selected geometric parameters are collated in the caption 
to Figure 2.  While the crystal structure of L2H2 is not available for comparison, that of the 4-
methoxy analogue, L5H2, is available [70].  In L
2H2 the formally C1=S1 thione bond is 
1.6769(14) Å, that is, considerably shorter than the C1–S1 bond length of 1.748(3) Å in 11′.  
The other parameters of interest relate to the shortening of the C1–N1 bond in 11′ to 1.290(4) 
Å compared with 1.3441(17) Å in L5H2, and the small increase in the formally imine-C2=N2 
bond to 1.309(4) compared with 1.2798(18) Å in L5H2 [70]. 
 
 
Figure 2.  The molecular structure of the constituents of 11′ showing atom-labeling scheme 
and 70% probability displacement ellipsoids.  The 3-methoxysalicylaldehyde azine molecule 
in (b) is disposed about a crystallographic center of inversion with unlabeled atoms related by 


































































O1 = 2.0853(19), Sn–N2 = 2.176(3), S1–C1 = 1.748(3), N1–N2 = 1.394(3), N1–C1 = 
1.290(4), and N2–C2 = 1.309(4) Å.  Details of the intramolecular hydroxy-O–H…N(azine) 
hydrogen bond: H3o...N4 = 1.84(3) Å, O3…N4 = 2.598(4) Å with angle at H3o = 150(3)°. 
The major distortions in the coordination geometry about the tin atom in 11′ can be traced to 
the formation of five- (Sn,S1,N1,N2,C1) and six-membered (Sn,O1,N2,C2-C4) chelate rings 
by the tridentate ligand, resulting in tight S1–Sn–N2 [77.76(6)°] and O1–Sn–N2 [84.62(9)°] 
chelate angles.  Each chelate ring is essentially planar as seen in the values of the root mean 
square (r.m.s.) deviations of 0.047 Å [maximum deviation = 0.035(3) Å for the C1 atom] and 
0.025 Å [0.026(3) Å for C3] for the five- and six-membered rings, respectively.  The dihedral 
angle formed between the chelate rings is 2.81(9)°, indicating these are coplanar, and the 
dihedral angle between the terminal rings is 5.36(15)°, indicating the Schiff base di-anion is 
essentially planar. 
 
The second constituent of 11′ is a half a molecule of 3-methoxysalicylaldehyde azine, with 
the full molecule being generated by the application of crystallographic inversion symmetry.  
The molecule is constructed about a central azine-N4–N4i bond [1.401(5) Å for symmetry 
operation (i) -x, 3-y, -z] and features intramolecular hydroxy-O–H…N(azine) hydrogen bonds 
which close S(6) loops; see Figure 2 for details.  The crystal structure determination of this 
molecule has been reported several times and in two polymorphs.  A form is known [71] 
where the molecule is disposed about a center of inversion [N–N = 1.4025(14) Å], as in 11′, 
as well as a non-symmetric version [N–N = 1.402(5) Å] but, which approximates a 
centrosymmetric conformation [72]. 
 
To a first approximation, the molecular structure of 12, Figure 3, mirrors that found for the 
diphenyltin compound in 11′.  Thus, a similar coordination mode is adopted by the L1 di-
anion but, in this case, based on a value of τ = 0.0 [69], the coordination geometry is distorted 
trigonal-bipyramidal.  In this description, the Sn atom lies 0.6358(18) Å out of the basal plane 
defined by the S1, O1, N2 and C16 atoms [r.m.s. deviation = 0.0078 Å] in the direction of the 
axially-bound C17 atom.  This arises as the two widest angles, that is, S1–Sn–O1 
[145.67(9)°] and N2–Sn–C16 [145.45(15)°] are virtually identical.  The Sn-S1 [2.5475(8)] 
and Sn-N2 [2.257(3)] bond lengths are, respectively, approximately 0.05 Å shorter and 0.08 
Å longer in 12 than the equivalent bonds in 11′, while the Sn-O1 bond lengths remain the 




































































Figure 3.  The molecular structure of the constituents of 12 showing atom-labeling scheme 
and 70% probability displacement ellipsoids.  Selected interatomic parameters: Sn–S1 = 
2.4982(12), Sn–O1 2.085(3), Sn–N2 = 2.257(3), S1–C1 = 1.751(4), N1–N2 = 1.396(5), N1–
C1 = 1.306(5), and N2–C2 = 1.288(5) Å. 
 
The five- and six-membered chelate rings in 12 exhibited r.m.s. deviations of 0.080 Å 
[maximum deviation = 0.071(3) Å for the N2 atom and 0.200 Å [0.189(1) Å for Sn], 
suggesting deviations from planarity.  Indeed, the five- and six-membered rings may each be 
described as having an envelope conformation where, for the smaller ring, the Sn atom lies 
0.248(6) Å out of the plane defined by the remaining four atoms [r.m.s. deviation = 0.0056 
Å].  The envelope is more pronounced for the larger ring with the Sn atom 0.612(5) Å above 
the plane [r.m.s. deviation = 0.0229 Å].  The dihedral angle between the chelate rings is 
17.88(12)° but this reduces to 12.1(2)° when the angle between the planar regions is 
computed.  The dihedral angle between the outer rings is 6.2(2)°. 
 
Thus far, no specific mention of the tin-bound substituents in 11′ and 12 has been made.  The 
Sn–C bond lengths in 11′ are equivalent at 2 × 2.134(3) and, in turn, these are experimentally 
equivalent to those in 12, that is, 2.134(4) Å [Sn–C16] and 2.128(4) Å [Sn–C17].  A 
difference is seen in the C–Sn–C angles, however.  Thus, in 11′, this angle is 121.46(12)° 
which is significantly wider than the equivalent angle of 114.82(18)° in 12.  This disparity is 
emphasized in the overlay diagram shown in Figure 4, as are the differences in the relative 




































































Figure 4.  Overlay diagram of the R2Sn(L
2) molecules in 11′ (R = Ph; red image) and 
inverted-12 (R = Me; blue image) whereby the five-membered rings are coincident. 
 
3.3.2. Supramolecular structures 
The most notable aspect of the molecular packing of 11′ is the formation of eight-membered 
{…HNCS}2 synthons through the agency of amine-N–H
…S(thiolate) hydrogen bonds between 
centrosymmetrically related Ph2Sn(L
2) molecules, Figure 5(a).  Additional interactions 
between molecules of note are of the type π(chelate ring)…π(oxidobenzylidene) stacking as 
illustrated in Figure 5(b).  Such interactions are increasingly being recognized as being 
important in providing points of contact in coordination chemistry [73] and computational 
chemistry indicates these provide energies of stabilization greater than conventional π-
stacking interactions between organic residues [74].  The dimeric aggregates are connected 
into a supramolecular layer in the ab-plane via L1-imine-C–H…O(hydroxy) and imine-C–
H…O(methoxy) interactions as shown in Figure 5(c).  In essence, each 3-
methoxysalicylaldehyde azine molecule links four symmetry related Ph2Sn(L
2) molecules.  
The layers stack along the c-axis direction, being connected by tin-bound-phenyl-C-H…π(Sn-
phenyl, oxidobenzylidene) and azine-methoxy-C-H…π(N-phenyl) interactions to consolidate 




































































Figure 5. Molecular packing in the crystal of 11′: (a) a view of the supramolecular dimer 
sustained by amine-N–H…S(thiolate) hydrogen bonds, shown as orange dashed lines [N3–
H3n…S1i: H3n…S1i = 2.60(3) Å, N3…S1i = 3.380(3) Å and angle at H3n= 150(3)° for 
symmetry operation (i) 1-x, 2-y, -z], (b) a view of the dimer aggregate connected by π(chelate 
ring)…π(oxidobenzylidene) stacking interactions [Cg(Sn,O1,N2,C1-C3)…Cg(C3-C8)ii = 
3.8613(15) Å and angle of inclination = 2.13(11)° for (ii) -x, 2-y, -z] shown as pink dashed 
lines, (c) supramolecular layer whereby the aggregate shown in (a) is connected by L2-imine-
C–H…O(hydroxy) and imine-C–H…O(methoxy) interactions (blue dashed lines) [C2–
H2…O3: H2…O3 = 2.40 Å, C2…O3 = 3.336(4) Å and angle at H2 = 168°; C34–H34...O2iii: 
C34–H34...O2iii = 2.40 Å, C34...O2iii = 3.230(4) Å  and angle at H34 = 146° for (iii) x, 1+y, z], 
and (d) a view of the unit-cell contents in projection down the b-axis with C–H…π 
interactions shown as purple dashed lines [C18–H18…Cg(C22-C27)iv: H18…Cg(C22-C27)iv = 
2.79 Å and angle at H18 = 148°; C19–H19…Cg(C3-C8)iv: H19…Cg(C3-C8)iv = 2.73 Å and 


































































H35c = 133° for (iv) x, 3/2-y, -1/2+z and (v) x, 5/2-y, 1/2+z].  In (a)-(c), non-participating 
hydrogen atoms have been omitted for clarity. 
 
The most prominent aspect of the molecular packing of 12 is the formation of supramolecular 
chains supported by amine-N–H…O(phenoxide) hydrogen bonding.  The chains are aligned 
along the a-axis and have helical topology, being propagated by 21-screw symmetry, Figure 
6(a).  Further stability to the aforementioned chains is provided by secondary bonding [73,75] 
of the type Sn…S, well known in organotin chemistry [76].  As detailed in Figure 6(b), the 
sulfur atom approaches the tin atom from the basal plane to establish a 5+1 coordination 
geometry; the C17–Sn–S1 angle = 157.48(11)°.  When considered in conjunction with the 
hydrogen bonding, six-membered, {…HNCS…SnO} heterosynthons are established.  The 
chains are assembled into a three-dimensional architecture by amine-N-phenyl-C–
H…π(oxidobenzylidene) interactions as each chain forms two donor and two acceptor 




































































Figure 6. Molecular packing in the crystal of 12: (a) a view of the supramolecular helical 
chain sustained by amine-N–H…O(phenoxide) hydrogen bonds, shown as orange dashed lines 
[N3–H3n…O1i: H3n…O1i = 2.26(4) Å, N3…O1i = 3.089(5) Å and angle at H3n = 160(3)° for 
symmetry operation (i) 1/2+x, 1/2-y, 1-z], (b) detail of the Sn…S secondary bonding [Sn…S1ii 
= 3.4928(12) Å for (ii) -1/2+x, 1/2-y, 1-z] within the chain shown in (a) and the resulting six-
membered, {…HNCS…SnO} heterosynthon, and (c) a view of the unit-cell contents in 


































































Chains are connected by amine-N-phenyl-C–H…π(oxidobenzylidene) interactions [C12–
H12…Cg(C3-C8)iii: H12…Cg3iii = 2.98 Å and angle at H12 = 129° for (iii) 1/2-x, 1-y, 1/2+z] 
shown as purple dashed lines. 
 
3.4. Cytotoxic activity  
Compounds 1-16 were screened for their cytotoxicity against a panel of ten cancer cell lines, 
HT29, U87, SJ-G2, MCF-7, A2780, H460, A431, DU145, BE2-C, and MIA cell lines and 
one normal cell line, MCF-10A (Table 1). However, it was not possible to determine the 
cytotoxicity values of 7 due to its insolubility in 100% DMSO at 1mM concentration. 
Cisplatin was used as a positive control to induce cell death. The growth inhibition 
concentration of the compounds required to inhibit 50% cell proliferation (GI50) were 
recorded after 72 hours of cell exposure to the compounds. The stability of the compounds in 
DMSO and in a mixture of DMSO and H2O were studied by UV-vis spectroscopic analysis, 
where the spectra remained unchanged after 72 hours which indicated that the compounds 
were stable in both solvent systems.  
 
The cytotoxicity evaluation of the 2-hydroxy-3-methoxybenzyl thiosemicarbazone Schiff 
base analogues (1 and 2) revealed an increase in potency when a methyl substituent was 
attached to the α-nitrogen atom, where 1 exhibited 10 to 20 times higher anti-proliferative 
activity as compared that of 2, 3, and 4 in the panel of cancer cell lines tested. Table 1 shows 
the high level of cytotoxic potency of 1 against HT-29, A2780, A431, BE2-C, and MIA cell 
lines. Compound 1 was approximately ~10-100 times more potent than similar synthesized 
structures, 2-[(1E)-({[(Benzylsulfanyl)methanethioyl]amino}-imino)methyl]-6-
methoxyphenol (SBOVaH) [25] and 2-hydroxy-5-methoxybenzaldehyde-N(4)-
methylthiosemicarbazone (H2dmmt) [8] against all the cancer cell lines tested, except for the 
DU145 cell line. 1 also showed excellent cytotoxicity against the panel of cancer cell lines 
compared to the reference drug (cisplatin). No obvious cytotoxicity pattern was observed for 
2 which was similar to that of a similar analogue, SBOVaH [25]. In contrast, the 2,3-
dihydroxybenzyl thiosemicarbazone Schiff bases (3 and 4) showed a different pattern of 
cytotoxicity, which could be attributed to the phenyl group attached to the α-nitrogen, where 
the phenyl group potentially facilitates the binding to biological molecules by π interactions 
[23]. Compounds 2 and 4 were similar in structure, with the difference only in the methoxy 


































































was more active than 2 in all cancer cell lines tested. This was possibly due to the formation 
of hydrogen bonding interactions of two hydroxyl groups with the active site of amino acids 
of various enzymes in cancer cells [77]. Compound 3 showed poorer cytotoxicity at the 25 
µM single point dose evaluation pre-screening and was not selected for further GI50 
determination, as it was considered to be inactive. The cytotoxicity of the Schiff bases was 
tested using the non-cancerous normal human breast cell line (MCF10A) where 1 showed 
lower toxicity towards the normal cells, which was evident from its higher GI50 values (less 
active) as compared to the GI50 values of most of the cancer cells, except U87, H460 and 
DU145. Compound 4 also exhibited higher GI50 values against MCF10A than HT29, MCF-7 
and A2780. This suggested that 1 and 4 exhibited notable anticancer properties against 
certain cancer cells as compared to normal cells.  
 
The cytotoxicity of the tin(IV) compounds are comparable to that of related compounds [25] 
where the diphenyltin(IV) compounds exhibited higher activities against certain cell lines as 
compared to their Schiff bases and other tin(IV) compounds. In particular, 5 showed higher 
cytotoxicity than its Schiff base (1) towards MCF-7, A2780, H460 and DU145 cells. It was 
also observed that 5 exhibited 2.5-fold lower activity than 1 in MIA cells. Compounds 8 and 
11 exhibited higher activity than 3 and 2 respectively across all cancer cell lines. In a similar 
vein, compound 14 was more active than 4 in all cells, except MCF-7, A2780 and H460 cells. 
The dimethyltin(IV) (6, 9, 12, and 15) and tin(IV) (10, 13, and 16) compounds exhibited no 
significant difference as compared to their Schiff bases. It can be concluded that the presence 
of two phenyl groups attached to the tin atom at the center improved cytotoxicity against all 
tested cancer cell lines. The planarity of the aromatic π system makes it available for stacking 
and easier penetration into the double helix of the DNA of cancer cells [78]. Overall, the 
cytotoxicity data indicated that HT29, MCF-7, A2780, A431, BE2-C, and MIA were more 
sensitive, whereas H460 and DU145 cells were more resistant against the Schiff bases and 
tin(IV) compounds than cisplatin that were investigated in this study. By comparing the 
toxicity of the compounds tested, all tin(IV) compounds (5-16) showed lower toxicity in 
MCF10A cells as the GI50 values of MCF10A were higher (less active) than the GI50 values 
of certain cancer cells. However, MCF10A is positive for telomerase reverse transcriptase 
[79] which is known to be up-regulated in many cancer cells as well. The decrease in cell 
viability after treatment with synthesised compounds may be due to the inactivation of this 
enzyme.  The use of MCF10A in this study is to act as a benchmark for the cytotoxicity data 


































































Table 1. In vitro cytotoxicity of tin(IV) compounds (5-16) derived from thiosemicarbazone Schiff bases (1-4) against several cell lines, 
determined by MTT assay and expressed as GI50 values with standard error. GI50 is the concentration at which cell growth is inhibited by 50% 72 
hours post-incubation. 
a ‘nd’ = not determine; b percentage growth inhibition at 25 μM compound concentration 
                             
Compounds 
Growth inhibition concentration, GI50 (µM) 
HT29 U87 MCF-7 A2780 H460 A431 DU145 BE2-C SJ-G2 MIA MCF10A 
1 0.09 ± 0.06 0.26 ± 0.11 0.12 ± 0.08 
0.037 ± 
0.07 
0.42 ± 0.19 0.09 ± 0.06 nd 0.03 ± 0.02 0.15 ± 0.03 0.04 ± 0.02 0.43 ± 0.29 
2 1.80 ± 0.22 3.5 ± 0.40 1.9 ± 0.46 2.0 ± 0.40 1.5 ± 0.27 2.4 ± 0.26 5.1 ± 0.58 1.0 ± 0.15 2.5 ± 0.77 2.1 ± 0.49 3.3 ± 0.26 
3b > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
4 0.29 ± 0.25 1.6 ± 0.29 0.03 ± 0.01 
0.041 ± 
0.02 
1.0 ± 0.03 1.4 ± 0.43 2.1 ± 0.09 0.7 ± 0.51 0.8 ± 0.49 2.5 ± 1.2 1.5 ± 0.40 
5 0.05 ± 0.02 0.14 ± 0.06 0.02 ± 0.00 
0.020 ± 
0.00 
0.22 ± 0.06 0.07 ± 0.04 0.86 ± 0.42 0.02 ± 0.00 0.09 ± 0.04 0.11 ± 0.09 0.15 ± 0.08 
6 0.30 ± 0.05 6.9 ± 5.1 0.13 ± 0.03 0.20 ± 0.01 1.3 ± 0.53 0.35 ± 0.12 5.0 ± 3.1 0.15 ± 0.03 0.48 ± 0.14 0.15 ± 0.03 1.0 ± 0.71 
7 nd nd nd nd nd nd nd nd nd nd nd 
8 0.15 ± 0.07 0.38 ± 0.10 0.10 ± 0.05 0.15 ± 0.04 0.60 ± 0.10 0.49 ± 0.31 0.50 ± 0.18 0.15 ± 0.04 0.42 ± 0.18 0.23 ± 0.07 0.34 ± 0.15 
9 0.36 ± 0.07 2.2 ± 0.33 0.22 ± 0.04 0.26 ± 0.01 1.4 ± 0.67 1.2 ± 0.81 9.1 ± 3.4 1.5 ± 0.39 1.6 ± 1.2 0.79 ± 0.36 3.2 ± 0.33 
10 0.09 ± 0.06 3.5 ± 3.3 0.09 ± 0.07 0.10 ± 0.08 >50 nd 25 ± 4.00 0.15 ± 0.11 0.22 ± 0.04 0.95 ± 0.21 0.81 ± 0.60 
11 1.0 ± 0.35 0.57 ± 0.13 0.31 ± 0.13 0.27 ± 0.01 1.1 ± 0.03 1.1 ± 0.26 1.4 ± 0.20 0.29 ± 0.06 0.44 ± 0.11 0.35 ± 0.08 1.2 ± 0.41 
12 1.8 ± 0.38 4.8 ± 0.75 1.6 ± 0.75 2.1 ± 0.43 2.0 ± 0.18 2.8 ± 0.46 4.8 ± 0.73 1.1 ± 0.20 1.3 ± 0.54 2.0 ± 0.88 3.2 ± 0.07 
13 1.7 ± 0.74 3.7 ± 1.3 2.6 ± 0.48 2.6 ± 0.37 3.2 ± 0.15 2.6 ± 0.22 5.3 ± 0.67 1.8 ± 0.07 5.0 ± 1.97 3.3 ± 0.72 4.4 ± 0.60 
14 0.19 ± 0.05 0.32 ± 0.04 0.12 ± 0.03 0.16 ± 0.04 0.53 ± 0.19 0.38 ± 0.19 0.20 ± 0.05 0.13 ± 0.02 0.20 ± 0.03 0.10 ± 0.02 0.37 ± 0.08 
15 0.12 ± 0.03 0.40 ± 0.07 0.10 ± 0.03 0.21 ± 0.05 0.83 ± 0.37 0.27 ± 0.11 0.56 ± 0.27 0.20 ± 0.05 0.23 ± 0.03 0.17 ± 0.05 0.30 ± 0.02 
16 0.18 ± 0.02 0.44 ± 0.06 0.17 ± 0.08 
0.27 ± 
0.023 
0.47 ± 0.07 0.26 ± 0.03 0.42 ± 0.15 0.25 ± 0.05 0.26 ± 0.02 0.23 ± 0.07 0.34 ± 0.02 



































































A series of twelve tin(IV) compounds derived from four thiosemicarbazone Schiff bases have 
been synthesized and characterized by physicochemical and spectroscopic techniques as well 
as X-ray crystallographic analysis. X-ray crystallography indicated a highly distorted 
coordination geometry trigonal-bipyramidal for Ph2Sn(L
1) in 11′ and for Me2Sn(L
1) in 12. An 
interesting pattern of cytotoxicity was observed where compound 1 was selectively active 
against HT29, A2780, A431, BE2-C and MIA, while 3 was inactive against all cancer cells. 
Both were similar in structure, the difference being the methoxy (1) and hydroxyl (3) 
substituent at the meta position of the phenyl ring. In contrast, compound 4 having a hydroxyl 
group at phenyl ring demonstrated greater activity than compound 2 which had a methoxy 
group. Diphenyltin(IV) compound 5 displayed excellent activity in the range of 0.016 – 0.22 
μM against all the cancer cells tested. Overall, diphenyltin(IV) compounds showed the most 
promising anticancer potential. Based on findings in this study, thiosemicarbazone Schiff 
bases and their tin(IV) compounds have significant anticancer potential and further 
mechanism of action and in vivo studies are required to determine the action of these 
compounds in vivo for better intracellular understanding. 
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Highlights 
 Thiosemicarbazone Schiff bases 1 and 4 are useful lead candidates for the future organic drug 
design development to treat cancers.  
 Trigonal bipyramidal diphenyltin(IV) compounds 5, 8, 11 and 14 exhibited excellent cytotoxic 
activity against a panel of ten cancer cell lines tested but minimal toxicity against MCF-10A 
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